T1d Progression Risk And Monitoring Frequency

---
name: t1d-progression-risk-and-monitoring-frequency
description: For a person with confirmed islet autoantibodies (early-stage type 1 diabetes), state the numerical progression risk to Stage 3 T1D by stage and age, set the age-stratified monitoring frequency (metabolic and HbA1c), apply the ≥10% longitudinal HbA1c rise → OGTT rule, and give the standard risk-modifier and communication framing. Use when a clinician asks how often should I monitor this Stage 1 child, what's the risk of this teenager progressing to insulin, adult with GAD positive what's the 5-year risk, my patient's HbA1c has risen 12% is that important, single autoantibody how often to retest, or how to counsel a family about progression risk. Grounded in Phillip et al. Diabetologia 2024 international staging and monitoring consensus, cross-referenced with Hussain et al 2026 IDF Europe roadmap.
---

# T1D Progression Risk & Monitoring Frequency

Convert a stage into two concrete numbers a family and clinician can act on: **the risk of progressing to clinical (Stage 3) T1D**, and **how often to check**.

---

## Step 1 — Confirm the stage first

This skill assumes staging has already been done via `t1d-staging-classifier` from a **confirmed** autoantibody result (second sample + 2 independent methods).

If the person is only single-antibody positive on a single unconfirmed sample → run confirmation first; do not counsel or set a monitoring schedule from an unconfirmed positive.

---

## Step 2 — State the progression risk (use a single, consistent number frame)

Use these figures. Communicate as a **single-number frame** ("~1 in 3 chance in the next 2 years") rather than layering multiple statistics.

### Single confirmed autoantibody (persistent)

- **10-year risk of Stage 3 T1D ≈ 14.5%**
- **~50% of children with a single autoantibody revert to negative** over time
- Vs general-population baseline of **0.3% lifetime risk** — the risk is elevated but the majority will NOT progress
- **No indication for teplizumab**

### Stage 1 T1D (≥2 confirmed antibodies, normoglycaemic, asymptomatic)

| Age group | Risk of Stage 3 by 5 years | By 10 years | Lifetime |
|---|---|---|---|
| **Children / adolescents (<18 y)** | **~44%** | **~70%** | **Near 100%** |
| **Adults (≥18 y)** | **~15%** | **~40%** | Progression continues but slower; lifetime approaches but does not always reach 100% |

### Stage 2 T1D (≥2 confirmed antibodies + dysglycaemia, asymptomatic)

| Age group | Risk of Stage 3 within 2 years |
|---|---|
| **Children / adolescents (<18 y)** | **~32%** (i.e. ~1 in 3 within 2 years) — near-certain lifetime |
| **Adults (≥18 y)** | **~5–10%** within 2 years — slower course |

### Key framing rules

- **Once ≥2 autoantibodies are confirmed, family history of T1D no longer changes the progression risk** — the risk is driven by the biology, not the pedigree
- **Children progress faster than adults** at every stage
- **Progression is not linear** — a Stage 1 individual can stall for years then progress rapidly, or vice versa
- **Reversion (Stage 1 → back to single or negative)** is possible but uncommon at ≥2 antibodies; more common with single-antibody status

---

## Step 3 — Apply risk-modifying factors

Progression risk is faster (all else equal) when:

- **Younger age at antibody detection** — a 2-year-old with Stage 1 progresses faster than a 15-year-old with Stage 1
- **IA-2A positivity** — IA-2 antibodies are particularly informative for near-term progression
- **Persistence of antibodies over multiple samples** — a stable-positive is higher risk than a fluctuating positive
- **Presence of other autoimmune disease** — coeliac disease, autoimmune thyroid disease
- **Higher antibody titre / more antibodies positive** (3–4 antibodies > 2 antibodies)

**Slower** (relative) progression:

- **Adult-onset** islet autoimmunity
- **Isolated GAD65 positivity** (often, though not always) — sometimes overlaps with LADA phenotype
- **Absence of IA-2A**

Use these to nuance the base rate — do not override the age × stage table above.

---

## Step 4 — Set the monitoring frequency (age-stratified)

### Single confirmed autoantibody, normoglycaemic ("At Risk")

| Age at detection | Retest schedule |
|---|---|
| **<3 years** | Every 6 months for 3 years, then annually for 3 years, then stop if no progression |
| **3–17 years** | Annually for 3 years, then stop if no progression |
| **Adults (≥18 y)** | Every 3 years |

If negative on all subsequent tests, stop routine retesting and counsel on symptom awareness.

### Stage 1 T1D (≥2 antibodies, normoglycaemic)

Metabolic monitoring = random glucose + HbA1c; OGTT if triggered.

| Age | Metabolic (random glucose) | HbA1c |
|---|---|---|
| **<3 years** | **Every 3 months** | Every 12 months |
| **3–9 years** | **At least every 6 months** | Every 12 months |
| **9–17 years** | **At least every 12 months** | Every 12 months |
| **Adults (≥18 y)** | Every 12 months (or per specialist judgement, given slower progression) | Every 12 months |

**Trigger for OGTT (any age):** a **≥10% relative rise in HbA1c from the confirmed-positive baseline**, even when the absolute HbA1c is still within the normal range. This is one of the earliest reliable signals of transition from Stage 1 to Stage 2 in children.

*Example:* baseline HbA1c 5.0% (31 mmol/mol) → new HbA1c 5.6% (38 mmol/mol) = 12% relative rise → do an OGTT even though 5.6% is still "prediabetic" not diabetic-range.

### Stage 2 T1D (≥2 antibodies + dysglycaemia)

- **Metabolic monitoring every 3 months** (random glucose + symptom check; consider CGM if not already in use)
- **HbA1c every 6 months**
- **Verify abnormal glucose findings** with **≥2 of** FPG / OGTT / HbA1c / CGM before escalating to a Stage 3 diagnosis or initiating insulin
- Coordinate with disease-modifying therapy evaluation (see `teplizumab-eligibility-and-course`)

---

## Step 5 — What to do when the person progresses stages during monitoring

- **Single IAb → multiple IAb** → move to Stage 1 monitoring cadence; re-counsel on the risk numbers
- **Stage 1 → Stage 2** (dysglycaemia detected) → move to Stage 2 cadence; **specialist referral**; discuss teplizumab eligibility
- **Stage 2 → Stage 3** (meets ADA diagnostic criteria) → clinical T1D care; start insulin per glycaemic status and symptoms; assess for DKA at presentation
- **Any DKA presentation** during monitoring = a failure to detect the transition earlier — review why the surveillance signal was missed, and refresh family education about symptoms

---

## Step 6 — Communication rules

When speaking with the person / family:

- **Plain language.** Avoid stage jargon at first; explain in terms of "autoantibodies show that the immune system is starting to react against the pancreas"
- **Distinguish "increased likelihood" from "diagnosis."** A single positive autoantibody is elevated risk, not diabetes. Confirmed ≥2 antibodies is early-stage T1D, but not yet "diabetes needing insulin"
- **Use one consistent number frame** — for a Stage 2 child, "about 1 in 3 chance of needing insulin within the next 2 years" (32%) rather than mixing 5-year, lifetime, and hazard ratios in the same sentence
- **Teach-back** — ask the family to repeat back what the result means in their own words. Correct gently if they've heard "your child has diabetes" from a Stage 1 result
- **Link every result to an action** — even a negative result has an action ("we'll recheck in a year"). Never end a counselling session without a concrete next step
- **Tailor by developmental stage** — young children: caregiver-led decisions; adolescents: shared decision-making; adults: autonomy-led
- **Acknowledge the emotional load** — parents of an antibody-positive child often carry more distress than the child. Anticipate this and offer psychosocial support proactively
- **Symptom safety net** — teach the polyuria / polydipsia / weight loss / vomiting escalation pathway at every visit. Written and verbal. Preventing DKA is the single most important outcome of monitoring

---

## Guardrails

- **Do not use these risk numbers to withhold monitoring** — a 15% 5-year risk in an adult is still ~1 in 7 progressing over 5 years. Every antibody-positive person deserves a structured monitoring pathway
- **Do not over-monitor** — testing a 15-year-old Stage 1 patient every 3 months creates anxiety without benefit. Stick to age-appropriate cadence
- **Do not use HbA1c alone in young children** — it can miss early dysglycaemia; the ≥10% relative rise rule captures the transition earlier than an absolute HbA1c threshold
- **Do not act on a single dysglycaemic value** at Stage 2 to declare Stage 3 — verify with ≥2 of FPG/OGTT/HbA1c/CGM before starting insulin. Random glucose fluctuations happen
- **Do not communicate "your child will get diabetes for sure"** based on Stage 1 — while lifetime risk is near-100% in children, some individuals stall for years or (rarely) revert. Use "very likely eventually" language
- **Do not use adult risk numbers for children** or vice versa — the difference is large (children ~44% at 5 years for Stage 1 vs adults ~15%)
- **Do not mix number frames** — pick one time horizon per conversation (5-year, 10-year, or lifetime) and stick with it
- **Do not skip psychosocial support** — anticipatory anxiety about a child developing diabetes is well documented and can persist. Loop in psychology / counselling from the start, not after distress becomes obvious
- **Do not treat family-history-positive and family-history-negative differently once ≥2 antibodies are confirmed** — the risk is the same. Historical assumptions that "no family history means lower risk" no longer apply after antibody confirmation

---

## Related MD2SKILL skills

- `t1d-staging-classifier` — must stage first before using this skill's tables
- `t1d-islet-autoantibody-screening-confirmation` — how the confirmed status was arrived at
- `teplizumab-eligibility-and-course` — for confirmed Stage 2 patients
- `nd-t2d-oad-selector` — differential in an adult with new hyperglycaemia and possible antibody-positive LADA

---

## Sources

Primary:

Phillip M, Achenbach P, Addala A, Albanese-O'Neill A, Battelino T, Bell KJ, Besser REJ, Bonifacio E, Colhoun HM, Couper JJ, Craig ME, Danne T, de Beaufort C, Dovc K, Driscoll KA, Dutta S, Ebekozien O, Elding Larsson H, Feiten DJ, Frohnert BI, Gabbay RA, Gallagher MP, Greenbaum CJ, Griffin KJ, Hagopian W, Haller MJ, Hendrieckx C, Hendriks E, Holt RIG, Hughes L, Ismail HM, Jacobsen LM, Johnson SB, Kolb LE, Kordonouri O, Lange K, Lash RW, Lernmark Å, Libman I, Lundgren M, Maahs DM, Marcovecchio ML, Mathieu C, Miller KM, O'Donnell HK, Oron T, Patil SP, Pop-Busui R, Rewers MJ, Rich SS, Schatz DA, Schulman-Rosenbaum R, Simmons KM, Sims EK, Skyler JS, Smith LB, Speake C, Steck AK, Thomas NPB, Tonyushkina KN, Veijola R, Wentworth JM, Wherrett DK, Wood JR, Ziegler A-G, DiMeglio LA. **Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes.** *Diabetologia* 2024;67(9):1731–1759. DOI: 10.1007/s00125-024-06205-5.

Cross-reference:

Hussain S, Tree T, Mathieu C, et al. **An international consensus on screening and monitoring early-stage type 1 diabetes: A roadmap to European implementation.** *Diabetes, Obesity and Metabolism.* 2026;28:3535–3556. DOI: 10.1111/dom.70569. Open-access CC-BY.